EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Progress in Cervical Cancer Biomarkers

Huangrong Ma, Yifu Wang, Miaoying Cai, Li Yang, Zhiyuan Xu

Clinical and Experimental Obstetrics & Gynecology · 03.04.2024 · 51 (4)

DOI: 10.31083/j.ceog5104089 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Experimental Obstetrics & Gynecology, online erschienen am 03.04.2024. Verfasst von Huangrong Ma und 4 weiteren Autor:innen. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shenzhen Science and Technology Program, Shenzhen Key Medical Discipline Construction Fund, Shenzhen Key Laboratory for cancer metastasis and personalized therapy.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Cervical cancer (CC) tops the list as the most prevalent malignant tumors of the female reproductive system and is one of the leading causes of cancer-related deaths in women worldwide. To improve the prognosis of CC, research has consistently focus on understanding innovative approaches. Biomarker-guided precision medicine is an important direction to improve prognosis. In this paper, we aim to deepen our understanding of CC biomarkers and accelerate their translation into clinical practice. Mechanism: Literature studies on biomarkers for CC were screened from 23 May 2019 to 23 May 2023. A comprehensive search was performed in NIH/NCBI/PubMed databases. Findings in Brief: There are numerous biomarkers that have a significant role in the diagnosis, prognosis, and treatment of CC. They can influence various processes such as tumour proliferation, invasion, infiltration, and apoptosis. They are also related closely to the sensitivity and resistance of radiotherapy and chemotherapy.

Conclusions

To date, multiple CC biomarkers have been identified. Few biomarkers have been successfully applied in clinical practice due to the lack of validation in large-scale clinical studies. Therefore, further clinical studies are necessary to realize the great potential in the clinic.

Förderung

  • Shenzhen Science and Technology Program
  • Shenzhen Key Medical Discipline Construction Fund
  • Shenzhen Key Laboratory for cancer metastasis and personalized therapy
  • Sanming Project of Medicine in Shenzhen

Zitieren

APA

Ma, H., Wang, Y., Cai, M., Yang, L., & Xu, Z. (2024). Progress in Cervical Cancer Biomarkers. Clinical and Experimental Obstetrics & Gynecology, 51(4). https://doi.org/10.31083/j.ceog5104089

Vancouver

Ma H, Wang Y, Cai M, Yang L, Xu Z. Progress in Cervical Cancer Biomarkers. Clinical and Experimental Obstetrics & Gynecology. 2024;51(4). doi:10.31083/j.ceog5104089

BibTeX
@article{Ma2024,
  author = {Ma, Huangrong and Wang, Yifu and Cai, Miaoying and Yang, Li and Xu, Zhiyuan},
  title = {Progress in Cervical Cancer Biomarkers},
  journal = {Clinical and Experimental Obstetrics & Gynecology},
  year = {2024},
  volume = {51},
  number = {4},
  doi = {10.31083/j.ceog5104089}
}
Kostenlos starten →